noting that its anti-PD1 therapy Keytruda cut the risk of disease recurrence or death by 31% after surgery in patients with urothelial carcinoma, a form of bladder cancer. At a median follow-up of ...

However there are limits to Keytruda’s benefits in bladder cancer, with the trial showing a response rate in just 21% of patients, though this was significantly higher than the 7% seen with ...

Keytruda for the treatment of locally advanced or metastatic urothelial cancer, a common type of bladder cancer. Pfizer said that the combined therapy is the first approved alternative to platinum ...

Bladder cancer: Keytruda is prescribed to adults to treat bladder cancer that’s: advanced or has spread from the bladder to other parts of the body. Keytruda is prescribed with the drug ...

NICE has axed funding for MSD’s Keytruda for second-line advanced bladder cancer in final guidance, despite an appeal from the company. Keytruda (pembrolizumab) was being reimbursed on an ...

The setback in bladder cancer is a small disappointment ... Combinations of Trodelvy and Keytruda have also advanced to late-stage testing against both breast and lung cancers.

After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S. The California biotech announced the decision ...

Astellas Pharma Inc., a pharmaceutical company conducting business in more than 70 countries around the world, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Padcev ...

Opens in a new tab or window The indication for sacituzumab govitecan (Trodelvy) in previously treated patients with locally advanced or metastatic urothelial cancer was withdrawn last month after ...

The withdrawal of the FDA accelerated approval for locally advanced or metastatic urothelial carcinoma, a type of bladder cancer, does not affect other indications of the therapy. The FDA has accepted ...

The positive opinion comes just one week after Keytruda was approved by the Medicines and Healthcare products Regulatory Agency in combination with Astellas/Pfizer’s Padcev (enfortumab vedotin) as a ...

DiPentino’s bladder cancer had returned in a lymph node ... Her new diagnosis made her eligible for Merck’s Keytruda immunotherapy after surgery. A third of 120 patients who sought a second ...